Monti J M, Monti D, Jantos H, Ponzoni A
Department of Pharmacology and Therapeutics, Clinics Hospital, Montevideo, Uruguay.
Neuropharmacology. 1995 Dec;34(12):1647-51. doi: 10.1016/0028-3908(95)00112-3.
The effects of the 5-HT1B receptor agonist CP-94,253 were compared with those of the mixed beta-adrenoceptor and 5-HT1A/B receptor antagonist (+/-)pindolol in rats implanted for chronic sleep recordings. CP-94,253 (5.0-10.0 mg/kg) significantly increased waking and reduced slow wave sleep (SWS) and REM sleep (REMS). At 2.0-4.0 mg/kg (+/-)pindolol reduced REMS. Pretreatment with (+/-)pindolol (2.0-4.0 mg/kg) reversed the effect of CP-94,253 on waking and SWS, while REMS remained suppressed. It is suggested that the 5-HT1B receptor together with other 5-HT receptor subtypes may have a direct regulatory action on sleep and waking in the rat.
在植入用于慢性睡眠记录的大鼠中,比较了5-HT1B受体激动剂CP-94,253与β-肾上腺素能受体和5-HT1A/B受体混合拮抗剂(±)吲哚洛尔的作用。CP-94,253(5.0-10.0毫克/千克)显著增加觉醒并减少慢波睡眠(SWS)和快速眼动睡眠(REMS)。在2.0-4.0毫克/千克时,(±)吲哚洛尔减少REMS。用(±)吲哚洛尔(2.0-4.0毫克/千克)预处理可逆转CP-94,253对觉醒和SWS的作用,而REMS仍受到抑制。提示5-HT1B受体与其他5-HT受体亚型可能对大鼠的睡眠和觉醒有直接调节作用。